Canagliflozin’s Impact on Bone Metabolism: Adaptive Mechanisms Unveiled

Canagliflozin’s Impact on Bone Metabolism: Adaptive Mechanisms Unveiled

The study investigated the effects of canagliflozin (CANA), a sodium-glucose transporter-2 inhibitor (SGLT2i), on bone health using genetically heterogeneous UM-HET3 mice. CANA is typically used to lower blood glucose levels independently of insulin but also induces various metabolic changes, including weight loss and impaired bone integrity. The research aimed to understand how CANA affects bone metabolism, given that SGLT2 is not expressed in osteoblasts or osteocytes, which are crucial for bone remodeling.

Next-Generation Skin Drug Delivery: Artificial Intelligence Solutions for Enhanced Therapeutic Precision and Barrier Navigation

Next-Generation Skin Drug Delivery: Artificial Intelligence Solutions for Enhanced Therapeutic Precision and Barrier Navigation

The article explores how artificial intelligence (AI) is transforming transdermal drug delivery systems (TDDS), offering innovative solutions to traditional challenges in drug administration. TDDS provides advantages over conventional oral and injectable methods by bypassing liver metabolism and enabling controlled drug release, but faces limitations due to the skin’s natural barrier properties.